PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a reasonable assumption given Veklury’s slow decline and reimbursement ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at ...